Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 15/20 | 0.81 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107304 | 0.94 | PTGS2 (0.85) | PTGS2PTGS1PTPN5TBXAS1 | |
| SCHEMBL5109155 | 0.90 | PTGS2 (0.79) | PTGS2PTGS1PTPN5TBXAS1 | |
| SCHEMBL5115827 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5117847 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL28742756 | 0.87 | PTGS2 (0.73) | PTGS2PTGS1PTPN5TBXAS1 | |
| SCHEMBL5109341 | 0.87 | PTGS2 (0.73) | PTGS2PTGS1 | |
| SCHEMBL5103122 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PTPN5 | |
| SCHEMBL5106342 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL5102776 | 0.83 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL5116259 | 0.81 | PTGS2 (0.76) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410994-B2 | Indole derivatives as anti-inflammatory agents | ROCHE PALO ALTO LLC (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060178420-A1 | Indole derivatives as anti-inflammatory agents | BROKA CHRIS A | 2006-08-10 | — | — | US | disclosed |
| US-7074939-B2 | Indole derivatives as anti-inflammatory agents | ROCHE PALO ALTO LLC (US) | 2006-07-11 | — | — | US | disclosed |
| CN-1261412-C | Indole derivatives as COXII inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-28 | — | — | CN | disclosed |
| US-20050176803-A1 | Indole derivatives as anti-inflammatory agents | BROKA CHRIS A (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1438289-B1 | INDOLE DERIVATIVES AS COX II INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6872744-B2 | Indole derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC (US) | 2005-03-29 | — | — | US | disclosed |
| CN-1561334-A | Indole derivatives as COXII inhibitors | HOFFMANN LA ROCHE (CH) | 2005-01-05 | — | — | CN | disclosed |
| EP-1438289-A1 | INDOLE DERIVATIVES AS COX II INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2004-07-21 | — | — | EP | disclosed |
| US-20030130337-A1 | Indole derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC | 2003-07-10 | — | — | US | disclosed |
| WO-2003029212-A1 | INDOLE DERIVATIVES AS COX II INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130337-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 4/4885PTGS1 3/4885PTPN5 2786/4885 |
| US-20050176803-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 5/4885PTGS1 3/4885PTPN5 2255/4885 |
| US-20060178420-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 5/4885PTGS1 3/4885PTPN5 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.